15074 studies found for:    research medical center
Show Display Options
Rank Status Study
1 Completed Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Condition: Occult Primary
Interventions: Drug: belinostat, carboplatin, paclitaxel;   Drug: carboplatin, paclitaxel
2 Recruiting Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
Condition: Ocular Infections, Irritations and Inflammations
Intervention: Drug: KPI-121
3 Recruiting Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Intervention: Drug: KPI-121
4 Active, not recruiting A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: bevacizumab;   Drug: docetaxel;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: pegfilgrastim
5 Terminated
Has Results
Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)
Conditions: Heart Failure;   Ventricular Dyssynchrony
Intervention: Device: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
6 Completed The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)
Condition: Blepharitis
Interventions: Drug: Azithromycin ophthalmic solution, 1%;   Drug: Placebo
7 Completed S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
8 Completed SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
9 Recruiting Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
10 Recruiting S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate
11 Active, not recruiting
Has Results
Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Concurrent temozolomide;   Radiation: Concurrent radiation therapy;   Drug: 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;   Drug: 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
12 Recruiting Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Drug: etoposide
13 Recruiting Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Conditions: Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive;   Plasmablastic Lymphoma
Interventions: Drug: EPOCH-R;   Drug: EPOCH-RR
14 Completed TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program
Condition: Coronary Artery Disease
Intervention: Device: TAXUS Express 2™
15 Recruiting S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Radiation: selective external radiation therapy;   Radiation: yttrium Y 90 ibritumomab tiuxetan
16 Active, not recruiting
Has Results
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin;   Drug: dexamethasone;   Drug: doxorubicin;   Drug: leucovorin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone;   Drug: Asparaginase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine;   Radiation: radiation therapy;   Drug: allopurinol;   Drug: bactrim
17 Unknown  Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
Conditions: Brenner Tumor;   Cognitive/Functional Effects;   Ovarian Carcinosarcoma;   Ovarian Choriocarcinoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Dysgerminoma;   Ovarian Embryonal Carcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mixed Germ Cell Tumor;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Polyembryoma;   Ovarian Sarcoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Stromal Cancer;   Ovarian Teratoma;   Ovarian Undifferentiated Adenocarcinoma;   Ovarian Yolk Sac Tumor;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage IC Primary Peritoneal Cavity Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Procedure: cognitive assessment;   Procedure: quality-of-life assessment
18 Unknown  Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720
Condition: Leukemia
Intervention: Other: laboratory biomarker analysis
19 Recruiting Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy;   Procedure: videothoracoscopy
20 Recruiting S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years